Articles(Arg15, Arg21) VIP: Evaluation of Biological Activity and Localization to Breast Cancer Tumors
Section snippets
Method
MCF-7 and T47D breast cancer cells were purchased from American Type Culture Collection (Rockville, MD) and cultured in DMEM containing 10% heat inactivated fetal bovine serum. The cells were cultured in 5% CO2/95% air at 37°C and were used in exponential growth phase. Routinely the cells, which are adherent, were split 1/10 weekly. VIP, VIPhybrid, and PACAP-27 were purchased from Peninsula Laboratories (San Carlos, CA).
For receptor binding studies, T47D cells were rinsed three times in SIT
Results
The ability of the VIP analogs to bind to T47D cells was determined. Fig. 1 shows that specific 125I-VIP binding was inhibited in a dose-dependent manner by VIP. Little specific binding was inhibited by 0.1 nM VIP, whereas almost all specific binding was inhibited by 1 μM VIP. Specific 125I-VIP binding was half maximally inhibited (IC50) by 0.6 nM VIP. Similarly, (Arg15, Arg21) VIP, (Arg20, Arg21) VIP, and (Arg15, Arg20) VIP had IC50 values of 0.8, 0.7, and 1.2 nM, respectively. Total binding
Discussion
Previously, 111In-octreotide has been used to localize gastrointestinal endocrine tumors using SPECT techniques [22]. This somatostatin agonist is not suitable for localizing breast tumors as only 50% of the breast specimens examined bind somatostatin with high affinity. Recently, it was found that all breast tumors examined bound VIP with high affinity 23, 29. Here, breast tumors were localized using radiolabeled (Arg15, Arg21) VIP.
123I-VIP was used to localize endocrine tumors in the
Acknowledgements
The authors thank Amy Guzzone for technical assistance.
References (30)
- et al.
Comparison of VIP-secretin receptors in rat and human lung
Peptides
(1981) - et al.
Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP inducing hormones in human gastric cancer cell line HGT-1homologous desensitization of VIP activity
Biochem. Biophys. Res. Commun.
(1984) - et al.
Multiple receptors for PACAP and VIP
Trends Pharmacol. Sci.
(1994) - et al.
Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide
Neuron
(1992) - et al.
One step synthesis of 18F labeled (18F)-N-succinimidyl-4-(fluoromethyl)benzoate for protein labeling
App. Radiation Isot.
(1994) - et al.
Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cAMP levels
Peptides
(1990) - et al.
Effects of guanine nucleotides on CNS neuropeptide receptors
J. Supramol. Struc.
(1981) - et al.
PACAP elevates cytosolic calcium in small cell lung cancer cell lines
Peptides
(1993) - et al.
High affinity binding of VIP to human lung cancer cell lines
Peptides
(1987) Pituitary adenylate cyclase activating polypeptide (PACAP)discovery and current status of research
Reg. Peptides
(1992)
Pharmacological characterization of a new type of VIP receptor on the melanoma-derived cell line IGR37
Vasoactive intestinal peptide and electrical activity influence neuronal survival
Proc. Natl. Acad. Sci. USA
A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes
Brain Res.
The VIP gene is expressed in non-small cell lung cancer cell lines
Biomedical Res.
An antagonist to vasoactive intestinal peptide affects cellular function in the central nervous system
J. Pharmacol. Exp. Ther.
Cited by (46)
Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases
2021, PeptidesCitation Excerpt :Also, radiolabeled VIP analogs, which bind to VPAC1, can be used to image cancer tumors. 18F(Arg1521)VIP localized to T47D breast cancer tumors in nude mice [126]. 64Cu-TP3982 localized to mammary tumors in MMTVneu transgenic mice [127].
Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [<sup>18</sup>F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide
2017, Bioorganic and Medicinal ChemistryCitation Excerpt :Procedures for the direct radiolabeling with fluorine-18 normally require harsh reaction conditions (strong bases, high temperatures) not compatible with heat-sensitive biomolecules [18]. Usually, site-specific radiolabeling of peptides with fluorine-18 is achieved using suitable radiolabeled intermediates or prosthetic groups [19–22]. This approach includes multistep reaction procedures and is, therefore, time-consuming.
Molecular imaging probes derived from natural peptides
2016, Natural Product ReportsChemoselective hydrazone formation between HYNIC-functionalized peptides and <sup>18</sup>F-fluorinated aldehydes
2006, Nuclear Medicine and BiologyVIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer
2006, Handbook of Biologically Active PeptidesExperiment assessment of mass effects in the rat: Implications for small animal PET imaging
2004, Nuclear Medicine and Biology